Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arrowhead Pharmaceuticals Inc shares valued at $185,213,587 were purchased by Sarepta Therapeutics, Inc. on Aug 13 ’25. At $19.99 per share, Sarepta Therapeutics, Inc. acquired 9,265,312 shares.
Also, Hamilton James C purchased 611 shares, netting a total of over 12,190 in proceeds.
Before that, Myszkowski Kenneth Allen had added 40,000 shares to its account. In a trade valued at $761,709, the Officer bought Arrowhead Pharmaceuticals Inc shares for $19.04 each.
As published in their initiating research note from Goldman on June 05, 2024, Arrowhead Pharmaceuticals Inc [ARWR] has been a Neutral and the price target has been revised to $31. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of September 19, 2023, Citigroup has initiated its “Neutral” rating for ARWR. Earlier on July 21, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ARWR stock.
Analyzing ARWR Stock Performance
On last trading session, Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] plunged -6.05% to $18.78. The stock’s lowest price that day was $18.14, but it reached a high of $18.88 in the same session. During the last five days, there has been a surge of approximately 16.94%. Over the course of the year, Arrowhead Pharmaceuticals Inc shares have dropped approximately -18.13%. Shares of the company reached a 52-week high of $21.84 on 02/07/25 and a 52-week low of $9.57 on 04/07/25.
Support And Resistance Levels for Arrowhead Pharmaceuticals Inc (ARWR)
According to the 24-hour chart, there is a support level at 18.32, which, if violated, would cause prices to drop to 17.86. In the upper region, resistance lies at 19.06. The next price resistance is at 19.34. RSI (Relative Strength Index) is 61.33 on the 14-day chart, showing neutral technical sentiment.
Is Arrowhead Pharmaceuticals Inc subject to short interest?
Stocks of Arrowhead Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-31 jumping by 0.32 million shares to 12.94 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 12.62 million shares. A jump of 2.48% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.42 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.42.
Which companies own the most shares of Arrowhead Pharmaceuticals Inc (ARWR)?
In terms of Arrowhead Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 30.48 in the next 12 months, up nearly 52.5% from the previous closing price of $19.99. Analysts anticipate Arrowhead Pharmaceuticals Inc stock to reach 52 by 2025, with the lowest price target being 24. In spite of this, 9 analysts ranked Arrowhead Pharmaceuticals Inc stock as Buy at the end of 2025. On May 12, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and downgraded coverage with a $40.
